A 58-year-old asymptomatic female presented for an annual mammogram.
The patient then underwent presurgical breast magnetic resonance imaging (MRI) (Figs. 5AeD) which demonstrated 2 confluent spiculated enhancing masses with rapid wash-in and delayed washout enhancement (progressive kinetics), heterogeneous on T2, isointense on T1 located in the left lower inner quadrant corresponding to area of mammographic and ultrasound findings. There was a focus of signal void artifact corresponding to a biopsy clip adjacent to the most posterior mass. There were several associated adjacent small sub centimeter enhancing satellite lesions. The entire area of abnormality on breast MRI measured approximately 5.5 Â 3.5 Â 2.5 cm.
Subsequently, the patient underwent a left breast lumpectomy with sentinel lymph node biopsy. The final pathology (Figs. 6AeC) revealed 2 different foci of well-differentiated neuroendocrine carcinoma of the breast measuring 15 mm and 8 mm in greatest microscopic dimension with negative margins and negative sentinel nodes (stage: pT1cN0M0).
Case report #2
A 62-year-old asymptomatic female presented for an annual mammogram.
Mammography (Figs. 7A and B) demonstrated a 0.9 cm oval partially obscured mass and an adjacent 0.5 cm oval circumscribed mass in the right breast upper outer quadrant at 10 o'clock.
Breast ultrasound, (Figs. 8AeC) showed a 1.0 Â 0.5 Â 0.7 cm oval hypoechoic circumscribed parallel mass without posterior acoustic features in the right breast 11 e 12 o'clock axis in the retroareolar region, corresponding to the largest mass on mammogram. Deep to this mass, there was a 0.6 Â 0.4 Â 0.8 cm oval anechoic circumscribed mass consistent with a simple cyst corresponding to the smallest mass on mammogram.
Ultrasound guided core needle biopsy was performed and yielded invasive ductal carcinoma (IDC) with neuroendocrine features, Nottingham grade 1, measuring up to 0.5 cm (Fig. 9) . Immunohistochemistry (Figs. 10AeE) showed tumor cells to be positive for E-cadherin, ER, PR, and synaptophysin. Immunohistochemistry was negative for human epidermal growth factor receptor 2.
The patient then underwent presurgical breast MRI, (Figs. 11AeD) which demonstrated a 1.2 Â 1.3 cm oval heterogeneously enhancing spiculated mass in the right retroareolar region with an adjacent biopsy clip corresponding to the largest mass on mammogram, ultrasound and to the biopsyproven carcinoma. Adjacent to this mass there was a 3.8 cm in maximum length area of ductal clumped non-mass-like enhancement corresponding to pathology-proven DCIS at lumpectomy.
Subsequently, the patient underwent right breast lumpectomy with sentinel lymph node biopsy which showed ductal carcinoma in situ and invasive mammary carcinoma with neuroendocrine and focal mucinous features, measuring up to 1.7 cm in greatest microscopic dimension, without margin involvement and negative sentinel lymph nodes (Figs. 12AeC), (stage: pT1cN0Mx).
Discussion

Etiology and demographics
Neuroendocrine carcinoma of the breast (NECB) is rare, accounting for less than 0.1% of all breast cancers and less than 1% of all neuroendocrine tumors (Table 1) [2] . This study calculated an incidence of <0.1% of total invasive carcinomas with most patients presenting in the sixth decade of life (mean age 64 years) [2] .
The histogenesis of neuroendocrine breast tumors is unclear, with 2 leading theories: that the tumor arises from endocrine differentiation of breast carcinoma rather than preexisting endocrine cells in the breast; or that the tumor arises from multi potential stem cells that differentiate along neuroendocrine carcinoma phenotype [3] .
Clinical and imaging findings
In 2003, the World Health Organization established formal diagnostic criteria for NECB requiring: the expression of neuroendocrine markers in more than 50% of the cell population, no evidence of other primary sites, and histologic evi- dence of a carcinoma in situ component [4] . Neuroendocrine markers include chromogranin, synaptophysin, and neuronspecific enolase. Neuroendocrine carcinomas of the breast are further histologically defined as solid, atypical/carcinoidlike, large cell-type, and small/oat cell-type. The most defining histologic features are cellular monotony, nuclear palisading, and pseudorosette formation [3] .
The number of cases with radiology findings has been too small to allow generalization of the imaging features. The imaging features of Primary Neuroendocrine Tumor of the breast have been previously described by only a small number of case reports [1,5e10] . The published cases describe nonspecific suspicious findings and do not provide ground for generalization of the imaging characteristics of this particular carcinoma ( Table 1 ). The described mammographic characteristics of this carcinoma include a high-density mass with spiculated, lobulated, or indistinct margins. The typical sonographic appearance of this cancer has been reported as a hypoechoic or heterogeneous mass, with irregular shape or microlobulated margins, and with normal sound transmission [7, 11] . On breast MRI, the tumor has been described as a mass of heterogeneously low signal intensity on T1-weighted images, and heterogeneously high signal intensity on T2-weighted images, and heterogeneous contrast enhancement with rapid initial enhancement and delayed washout [11] .
Given that the presence of carcinoma in situ is one of the required criteria for the diagnosis of NECB, it is of interest that in our case 1, there is presence of associated suspicious calcifications, which from an imaging/mammographic point of view suggests the presence of carcinoma in situ (later proved by pathology) and that in case 2, there is presence of associated linear clumped nonemass-like enhancement, which The imaging features demonstrated by our 2 cases, although suspicious for malignancy, are not specific. This was also noted in other published case reports of NECB (Table 2 ). This precludes the possibility of diagnosing NECB solely based on imaging characteristics. In these cases, biopsy is warranted.
Differential diagnosis
Primary neuroendocrine carcinoma of the breast is an in situ breast carcinoma, which expresses neuroendocrine markers in more than 50% of the cell population. Therefore, imaging findings carry the same differential as in situ breast carcinoma. A definitive diagnosis of primary neuroendocrine carcinoma of the breast can only be made by biopsy. In both cases, the imaging finding differential diagnosis includes invasive ductal carcinoma, fibroadenoma/phyllodes tumor, focal adenosis, abscess, invasive lobular carcinoma, radial scar, and stromal fibrosis (Table 3) . Most importantly, the findings found on all imaging modalities were considered suspicious for malignancy and required biopsy.
Treatment and prognosis
To date, there is no standard treatment protocol for primary neuroendocrine carcinoma of the breast. Optimal treatment requires simultaneous consideration of both the neuroendocrine and breast in situ carcinoma features [4] . Most cases are treated like adenocarcinoma of the breast with radical mastectomy and axillary clearance considered as a first line of treatment with adjuvant chemotherapy (Table 1) [18] . Differentiating "primary" from "metastatic" NECB is crucial because the latter does not justify submitting a patient to mastectomy and axillary node dissection [19] .
There is no consensus on the optimal adjuvant chemotherapeutic regimen. The most commonly used chemotherapeutic regimens include cisplatin and etoposide, adriamycin and cyclophosphamide, or 5 fluorouracil, epirubicin, and [20] . Wang et al. [2] found that radiation therapy did not prolong survival.
The prognosis for this rare carcinoma is controversial (Table 1) . Patient outcome is affected by histologic traits, which include the following: grade, mucin production, and apocrine differentiation [21] . Better prognosis is seen with well-differentiated carcinomas (eg, solid neuroendocrine carcinoma and atypical carcinoids), mucin production (eg, solid papillary carcinomas mucinous carcinomas), and apocrine differentiation [22e24].
Wei et al. [18] reported in a retrospective study of 74 patients with NECB that hormonal therapy, chemotherapy, and 
radiation therapy have not demonstrated an advantage in overall survival when compared to ductal carcinoma. Recent reports on small cell neuroendocrine carcinoma indicate that the size, stage of disease at the time of diagnosis, and expression of the ER and PR are important determinants of the prognosis [25, 26] . Higher grade, increased tumor size, and regional lymph node metastasis are associated with poor prognosis and decreased disease-free survival [27] . Mucinous differentiation and ER/PRs positivity are favorable prognostic factors [3] .
Clinical outcomes in the literature report a 15% local and 34% distant recurrence risk by 5 years among NECB patients [3] . The common sites for distant metastasis are bone and liver [18] . Wang et al. [2] reported median survival of patients with NECB cases to be shorter than that of invasive mammary carcinoma not otherwise specified cases (26 months in NEC; 34 months in IMC-NOS).
Significance to clinical practice
Imaging features of primary neuroendocrine carcinoma of the breast are suspicious for malignancy, but are not specific, precluding the possibility of arriving at the diagnosis solely based on imaging characteristics. The diagnosis requires biopsy showing expression of neuroendocrine markers in more than 50% of the cell population, the presence of ductal carcinoma in situ, and the absence of clinical evidence of concurrent primary neuroendocrine carcinoma of any other organ. 
